Gadodiamide

Gadodiamide is a gadolinium-based MRI contrast agent, used in MR imaging procedures to assist in the visualization of blood vessels. It is commonly marketed under the trade name Omniscan.

Gadodiamide
Clinical data
Other names2-[bis[2-(carboxylatomethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetate; gadolinium(+3) cation
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		i.v.
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Protein bindingnegligible
    Metabolismnot metabolized
    Elimination half-life77.8 minutes
    ExcretionKidney
    Identifiers
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC16H28GdN5O9
    Molar mass591.672g/mol g·mol−1
    3D model (JSmol)
     NY (what is this?)  (verify)

    Uses
    Further information: MRI contrast agent
    A bottle of Omniscan contrast agent.

    Gadodiamide is a drug i.e contrast medium used for cranial and spinal magnetic resonance imaging (MRI) and for general MRI of the body after intravenous administration. The product provides contrast enhancement and facilitates visualisation of abnormal structures or lesions in various parts of the body including the central nervous system (CNS). It does not cross an intact blood brain barrier but might give enhancement in pathological conditions.

    Adverse effects

    It has been associated with a toxic reaction known as nephrogenic systemic fibrosis (NSF) in some people with severe kidney problems.[1] No cases have been seen in people with normal kidney function.[2]

    A 2015 study found trace amounts of gadolinium deposited in the brain tissue of people that had received gadodiamide.[3] This is of unknown significance.[3]

    In the United States there are recommendations that one does not need to stop or altering breastfeeding while in Europe it is recommended that a mother throw out 24 hours of breast milk.[4]

    References
    1. Ibrahim, MA; Dublin, AB (January 2018). "Magnetic Resonance Imaging (MRI), Gadolinium". PMID 29494094. Cite journal requires |journal= (help)
    2. Canavese, C; Mereu, MC; Aime, S; Lazzarich, E; Fenoglio, R; Quaglia, M; Stratta, P (2008). "Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness". Journal of Nephrology. 21 (3): 324–36. PMID 18587720.
    3. Anderson, Pauline (2015-03-26). "Gadolinium Found in Brain Tissue". Medscape. Retrieved 14 April 2015.
    4. "Gadodiamide". Drugs and Lactation Database. 2006. PMID 30000472.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.